AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m. The …
Post
-
-
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a cyclin-dependent kinase …
-
Pineapples and green tea: FDA turns to public for new approaches to botanical drugs
The US Food and Drug Administration (FDA) is requesting public input on both the opportunities and challenges regarding drugs derived …
-
Ionis nets Zanvastro US approval in first for Alexander disease
Ionis Pharmaceuticals has secured an approval from the US Food and Drug Administration (FDA) for its therapy, zilganersen, in the …
-
FDA rallies HRT manufacturers amid US-wide estradiol patch shortage
The US Food and Drug Administration (FDA) has started working with six drug-device manufacturers involved in the production of transdermal …
-
AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m. The …
-
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a cyclin-dependent kinase …
-
Pineapples and green tea: FDA turns to public for new approaches to botanical drugs
The US Food and Drug Administration (FDA) is requesting public input on both the opportunities and challenges regarding drugs derived …
-
Ionis nets Zanvastro US approval in first for Alexander disease
Ionis Pharmaceuticals has secured an approval from the US Food and Drug Administration (FDA) for its therapy, zilganersen, in the …
-
FDA rallies HRT manufacturers amid US-wide estradiol patch shortage
The US Food and Drug Administration (FDA) has started working with six drug-device manufacturers involved in the production of transdermal …
-
Superluminal Medicines secures $60m to advance rare obesity therapy
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for …
-
Médunik and Biocodex sign exclusive agreement for Diacomit in Canada
Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an …
-
ESC 2026: oral and injectable GLP-1 comparisons under the spotlight
Treatments targeting glucagon-like peptide-1 (GLP‑1) receptors have come to play a pivotal part in the tools available when treating patients …
-
GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid …
-
Typewriter raises $56m Series A to progress non-viral gene therapy platform
Biotech startup Typewriter Therapeutics has emerged from stealth with $56m in capital as it looks to progress its non-viral in …
